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Abstract
Purpose The development of biomarkers and molecularly targeted therapies for patients with Ewing sarcoma (ES) in order to
minimisemorbidity and improve outcome is urgently needed. Here, we set out to isolate and characterise patient-derived ES primary
cell cultures and daughter cancer stem-like cells (CSCs) to identify biomarkers of high-risk disease and candidate therapeutic targets.
Methods Thirty-two patient-derived primary cultures were established from treatment-naïve tumours and primary ES-CSCs
isolated from these cultures using functional methods. By RNA-sequencing we analysed the transcriptome of ES patient-
derived cells (n = 24) and ES-CSCs (n = 11) to identify the most abundant and differentially expressed genes (DEGs).
Expression of the top DEG(s) in ES-CSCs compared to ES cells was validated at both RNA and protein levels. The functional
and prognostic potential of the most significant gene (neurexin-1) was investigated using knock-down studies and immunohis-
tochemistry of two independent tumour cohorts.
Results ES-CSCs were isolated from all primary cell cultures, consistent with the premise that ES is a CSC driven cancer.
Transcriptional profiling confirmed that these cells were of mesenchymal origin, revealed novel cell surface targets for therapy
that regulate cell-extracellular matrix interactions and identified candidate drivers of progression and relapse. High expression of
neurexin-1 and low levels of regulators of its activity, APBA1 and NLGN4X, were associated with poor event-free and overall
survival rates. Knock-down of neurexin-1 decreased viable cell numbers and spheroid formation.
Conclusions Genes that regulate extracellular interactions, including neurexin-1, are candidate therapeutic targets in ES. High
levels of neurexin-1 at diagnosis are associated with poor outcome and identify patients with localised disease that will relapse.
These patients could benefit frommore intensive or novel treatment modalities. The prognostic significance of neurexin-1 should
be validated independently.
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1 Introduction
Ewing sarcoma (ES) is a tumour of bone and soft tissues,
commonly arising in young people aged 10–25 years [1].
Multi-agent systemic chemotherapy, surgery and radiotherapy
have improved the outcome for some patients, although less
than two-thirds will survive 5 years beyond diagnosis.
Twenty-five percent of patients present with metastatic dis-
ease, most frequently in multiple sites including bone/bone
marrow/lungs or lungs only. These patterns of metastasis are
associated with overall survival rates of 10–20% and 40%,
respectively [2]. Disease progression occurs in approximately
50% of all patients, usually within two years of diagnosis.
Survival after recurrence is just 10–15% [3, 4]. Patients
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diagnosed with localised ES generally have a better outcome,
with 55 to 70% of them achieving 5 year event-free survival
[5]. However, 30–40% of patients with localised tumours will
develop multi-drug resistant (MDR) disease leading to relapse
and poor outcomes typically associated with widespread met-
astatic disease, with 5 year survival of less than 10% [6].
Identification of patients with localised disease that do badly
at diagnosis could mean they are offered more intensive or
alternative experimental treatments, which may improve out-
comes. For all patients that survive therapy, 1 in 10 will re-
lapse up to 20 years after initial diagnosis [7], many experienc-
ing treatment-induced morbidity [8–10]. Therefore, the devel-
opment of molecularly targeted therapies to minimise morbid-
ity and improve outcomes for patients with ES are urgently
needed.
ES has been described as a cancer stem cell-like driven
disease [11, 12], although this is controversial [13]. ES
stem-like cells (ES-CSCs) have the ability to both survive
chemotherapeutic insult and enable re-population of the tu-
mour at primary and/or secondary metastatic sites by self-
renewal (SR), migration and invasion [14]. Therefore, im-
proved outcome for some patients will only be achieved when
drugs to eradicate ES-CSCs are introduced into the clinic. We
have hypothesised that a combination of drugs to eradicate
ES-CSCs with cytotoxic chemotherapy to destroy the tumour
bulk will prevent the development of metastatic multi-drug
resistant (MDR) disease and improve patient outcomes. This
strategy may also minimise treatment-induced toxicity in case
the CSC targeted therapy and chemotherapy have synergistic
activity, allowing a reduction in the amount of chemotherapy
with no loss of activity.
Sarcoma- and ES-CSCs have most frequently been identi-
fied by cell surface expression of the glycoprotein prominin-1
(CD133) [11]. In addition, cell surface expression of the tyro-
sine kinase protein c-Kit (CD117), low affinity nerve growth
factor receptor (CD271) and octamer-binding transcription
factor 4 (OCT4, [12]) or intracellular aldehyde dehydrogenase
(ALDH [15]), the ability to form 3D spheres [16] and the
expression and activity of ATP-binding cassette (ABC) trans-
porter proteins [17] have been employed to enrich for CSC
populations. These studies have largely used established cell
lines, with a single study investigating ES-CSCs among pri-
mary patient-derived cells by investigating cell surface expres-
sion of CD133 [11]. However, marker-based enrichment
methods can fail to robustly isolate the complete CSC popu-
lation, reflected by CSC characteristics of CD133-negative
cells [18]. Moreover, expression of CSC related proteins
may fluctuate throughout the cell cycle [19] and be modified
by the cellular microenvironment [20], thereby reducing their
value.
In this study, we have adopted a functional approach to
enrich for ES-CSCs with MDR and SR ability from primary
patient-derived ES cells, as we reported previously in
osteosarcoma [21]. Since ES, like other gene fusion-driven
cancers of young people, have few recurrent mutations
[22–24] we used total ribonucleic acid (RNA) sequencing to
characterise patient-derived primary ES cells and daughter
ES-CSCs. By differential expression analysis [25], we com-
pared the transcriptome of patient-derived parental and daugh-
ter MDR/SR progeny to identify candidate drivers of the ES-
CSC phenotype. Potential associations with clinical outcome
and biological relevance of the most abundant differentially
expressed ES-CSC genes were explored to prioritise candidate
risk biomarkers and putative therapeutic targets, with the fu-
ture goal of developing more personalised therapeutic
strategies.
2 Materials and methods
2.1 Patient samples, primary patient-derived cell cul-
tures, cell lines and clinical data
Treatment-naïve tumours from 116 young people with a con-
firmed diagnosis of ES between 1998 and 2017 were includ-
ed, i.e., fresh tumours from which primary cultures were
established (n = 32, Additional file 5, Table S2), frozen tu-
mours (n = 47, Additional file 9, Table S6) and formalin-fixed
paraffin-embedded (FFPE) tumours (n = 37, Additional file 9,
Table S6). Informed consent and ethical approval for the col-
lection of the tumours was obtained through GenoEWING
(IRAS 167880, EDGE 79301). Immunohistochemistry
(IHC) was performed on frozen or FFPE tumour samples from
the Children’s Cancer and Leukaemia Group Tissue Bank
(MREC 98/4/023; biological study 2010 BS03) or the
Newcastle Biobank (LREC 17/ND/0361, IRAS 233551).
The minimum period of follow up for all patients was
24 months (730 days). Patients received risk-adapted neoad-
juvant and adjuvant chemotherapy with surgery, with or with-
out radiotherapy, to control primary and possibly metastatic
disease [26]. Cell lines were used as positive controls
(Additional file 1, Data S1). The results and methods de-
scribed in this study are based on the Reporting
Recommendation for Tumour Marker Prognostic Studies
(REMARK) guidelines [27].
Fresh tumours (n = 32) were obtained from patients under-
going surgery at the Royal Orthopaedic Hospital,
Birmingham between May 2015 and March 2018. Samples
were collected in 15 ml Leeds Antibiotic Media and
transported at room temperature to Leeds, where they
were processed immediately as previously described [21].
C e l l s a t t a c h e d t o b o n e we r e r emov e d u s i n g
trypsin:ethylenediaminetetraacetic acid (EDTA; 1:1; trypsin
0.25% and EDTA 0.1% both w/v in phosphate buffered saline
(PBS)) at 37 °C for 30 min.
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The prognostic potential of candidate drivers of ES-CSCs
was explored by IHC of tumours collected at diagnosis. The
potential association with clinical outcome was first explored
by IHC of frozen tumour samples mounted in Optimum
Cutting Temperature compound (OCT; Merck Biosciences)
from 47 patients (cohort 1). Tumours were collected between
1998 and 2006 from patients with a median age of 12 years,
range 5–20 years. The median follow up time and time to a
first event was 912 and 501 days, respectively; 57% of pa-
tients had an adverse event. The prognostic potential of the
most significant differentially expressed candidate driver gene
(neurexin-1) was assessed in a second cohort of 37 FFPE
tumours (cohort 2), collected between 2001 and 2017. The
median age of ES patients at diagnosis in cohort 2 was
13 years, range 2–38 years. The median follow up time and
time to a first event was 2499 and 1747 days, respectively;
36% of patients had an adverse event.
2.2 ES confirmation of cultured cells
Cytological features of patient-derived primary cells were con-
firmed by light microscopy (Zeiss Axioplan microscope; Zeiss,
UK) of haematoxylin stained cells centrifuged onto slides
(1000 g for 3 min; Rotix 32A Hettich Zentrifugen).
Fluorescence in situ hybridisation (FISH) using a Vysis
EWSR1 Break Apart FISH Probe (3 N5920, Vysis, Abbott
Laboratories Ltd., UK) and reverse transcriptase polymerase
chain reaction (RT-PCR) for Ewing sarcoma breakpoint region
1 (EWSR1)-erythroblast transformation specific (ETS) fusion
transcripts were used to check cells for pathognomonic EWSR1
gene rearrangements. Expression of CD99 antigen (CD99) was
confirmed by immunocytochemistry (ICC) of cytospins and
Western blotting [28] (Additional file 2, Data S2).
2.3 Phenotypic characterisation of ES cells
2.3.1 Self-renewing (SR) ability
A single cell (Poisson distribution probability of λ < 1 = 0.9)
was seeded into each well of 10 Primaria™ 96-well plates
(Corning) and the numbers of wells containing ≥ 5 cells were
recorded after 21 days by light microscopy (Olympus
CKX41) [21].Where possible, SR cell populations were prop-
agated to establish daughter cell cultures.
2.3.2 Response to cytotoxics
Patient-derived primary ES cells (1 × 103) and TC-32 (posi-
tive control, 6 × 103) cells were seeded in Primaria™ 6-well
plates (Corning), allowed to adhere overnight and then treated
with doxorubicin or vincristine (1–200 nM). After 72 h the
media were replaced, colonies maintained for an additional
7 days, fixed and stained with crystal violet (0.25% (w/v) in
methanol:ddH2O; Sigma-Aldrich) [29]. Colony numbers per
well were counted using Quantity One Software (Bio-Rad).
2.3.3 Migration
Migration over 72 h was determined as previously described
[21]. Migration index (MI) = total migrated area relative to the
size of the spheroid core at 0 h.
2.4 Transcriptome analysis using total RNA
sequencing and differential expression analysis
Total RNA libraries were prepared from 1 μg RNA with an
RNA integrity number > 9 extracted from ES primary patient-
derived cultures (n = 24) and ES-CSCs (n = 11) using a
TruSeq Stranded Total Library Preparation kit with Ribo-
Zero Human (Illumina®, CA, USA). Four samples were
pooled (100 ng per sample) before paired-end sequencing
using an Illumina® HiSeq3000 apparatus (151 cycles,
Illumina®). FASTQ files were downloaded and reads pre-
processed using cutadapt [30]. Briefly, low quality reads and
any adapter contamination were removed and post-trimmed
reads aligned to Gencode human 38 release 25 (GCh38_25)
by 2-pass alignment using Spliced Transcripts Alignment to a
Reference ([31]; STAR). Differential expression of RNAs be-
tween sample groups was identified using DESeq2 [25, 32].
Adjusted p values < 0.001 were considered significant.
The most significant differentially expressed RNAs from
the RNA sequencing data were validated using reverse tran-
scriptase quantitative polymerase chain reaction (RT-qPCR)
and confirmed at the protein level by ICC of cytospins
(Additional file 3, Table S1).
Gene lists were analyzed using the Search Tool for
Retrieval of Interacting Genes/Proteins (STRING) database
(http://string-db.org, [33]) to identify any interactions
between the genes and their reported biological function(s).
Interaction Confidence Scores (ICS) were assigned to each
protein association and ranked from 0 to 1, where 0 is least
likely to be correct and 1 most likely accurate. An ICS of 0.5
indicates that every second interaction might be a false posi-
tive. Therefore, only genes with an ICS of 0.5 or greater were
imported into Cytoscape v3.7.1 (cytoscape.org, supported by
NRNB and NIHR) for visualization. Genes predicted to be
expressed on the cell surface were identified by interrogating
an ES surfaceome gene expression database (www.imm.ox.
ac .uk/ research/uni ts -and-cent res /mrc-molecular -
haematology-unit/research-groups/rabbitts-group/more-from-
the-rabbitts-group/surfaceome-database, [34]). Using this tool
RNA species are classified as gold or silver, where a
classification of gold represents a protein with known cell
surface expression and silver a protein predicted to be
expressed at the cell surface [34]. The predicted subcellular
localisation of protein products in cancer and normal cells was
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confirmed by interrogation of the published literature and the
Human Protein Atlas database (www.humanproteinatlas.
org). The FASTQ files of sequenced ES and ES-CSCs are
available in the Research Data Leeds Repository (University
of Leeds), Burchill, Susan and Roundhill, Elizabeth (2020):
Total RNA sequencing of patient-derived Ewing sarcoma
and Ewing sarcoma CSCs University of Leeds [Dataset]
https://doi.org/10.5518/887
Following the removal of low-quality reads and adapter
contamination, 99 ± 1% (range 92–99%) of reads were
retained. Consistent with its role as a major effector of the
chromosome X inactivation process in females [35], expres-
sion of the X-inactive specific transcript (XIST) was low in
male RNA (mean normalised read count = 4 ± 5, range
0–22) and significantly higher in females (mean normalised
read coun t = 8326 ± 6112 , range 782–19 ,545 ;
p < 0.0000004). Confirming the pipeline for analysis of
genes in the pseudo-autosomal regions of the X and Y chro-
mosomes (Additional file 6, Table S3), there was a positive
correlation between the read count of CD99 by RNA se-
quencing and RNA detected by RT-qPCR (R2 = 0.898).
2.5 IHC of candidate genes and regulators of their
activity
Expression of the top significant differentially expressed
genes (DEGs) was evaluated at the protein level by IHC
(Additional file 4, Data S3). The level of expression was
semi-quantified using the H-score, assessing both the inten-
sity of staining and the percentage of positive cells [36],
independent of clinical outcome data.
2.6 Knock-down of neurexin-1 by shRNA and siRNA
ES cells were infected with neurexin-1 (sc-42,050-V) short
hairpin RNA (shRNA) lentiviral particles targeting both
neurexin-1α and -β isoforms or scrambled sequence controls
(sc-108,080; Santa Cruz Biotechnology, Inc.; each shRNA
pool containing 3–5 constructs [37]). Infected cells were se-
lected in puromycin (0.5 μg/μl; Sigma-Aldrich) for 10 days
before placing them in normal growth media. Knock-down of
protein expression after infection was confirmed by Western
blotting and ICC. Viable cell numbers over time (24–72 h)
were measured using a trypan blue exclusion assay [21] and
proliferation using Cell Trace™CFSE [38]. In the proliferation
assay, cells were labelled with carboxyfluorescein succinimidyl
ester (CFSE) (0.5 nM) and harvested at 24–72 h, after which
fluorescence was measured using an Attune NxT Flow
Cytometer (Thermo Fisher Scientific). The effect of doxorubi-
cin and vincristine treatment for 72 h on colony forming effi-
ciency was examined using a cytotoxicity assay (see
Phenotypic characterisation of ES cells, above).
SH-SY-5Y (1 × 106) cells, which express high levels of
neurexin-1 and were used as a positive control, were
electroporated (X-005, Nucleofector™ 2b Device (Amaxa,
Lonza, UK) with an siRNA scrambled control (siControl,
50 nM, sc-36,869, Santa Cruz Biotechnology, Inc) or
siRNA targeting neurexin-1 (siNRXN1, 50 nM, sc-42,050, a
pool of 3 target-specific 19–25 nt siRNAs, SantaCruz
Biotechnology, Inc). Knock-down of RNA expression was
confirmed by RT-qPCR. Single cells electroporated with
siNRXN1 or siControl were seeded into Ultra-Low
Attachment plates (Corning, supplied by VWR International,
UK) and 3D spheroid formation imaged by light microscopy
(Olympus CKX41) after 7 days. The numbers and sizes of
spheroids were quantified using ImageJ (NIH, USA).
Fig. 1 Characterisation of patient-derived ES and ES-CSC cultures
and response to cytotoxics. (A) Image of patient-derived primary ES
cells (sample number 32) labelled using a Vysis EWSR1 Break apart
FISH Probe. Red arrows = cells containing both a red and green immu-
nofluorescent signal, indicating an EWSR1 gene translocation. (B)
Representative ethidium bromide stained agarose gel illuminated by
UV-light of EWSR1-FLI1 RT-PCR products generated from patient-
derived primary ES cultures 14 and 15, confirming both cultures to con-
tain EWSR1-FLI1 products. Positive controls include TC-32 = EWSR1-
FLI1 type I (260 base pairs (bp)) and RD-ES = EWSR1-FLI1 type II
(326 bp). Negative control = TTC466 which contains an EWSR1-ERG
fusion. (C) ICC of patient-derived parental culture 27 for CD99. Red
arrow = positive CD99 membrane expression. (D) Western blot for
CD99 protein expression in patient-derived primary ES cell cultures 12,
9, 8, 11, 5, 13 and 14. Equal protein loadingwas confirmed by probing for
β-actin expression. Protein extract from TC-32 cells was included as a
positive control. M = molecular weight markers. (E) Light microscopy of
single cell derived colony 6 established from patient-derived primary ES
culture 23; 23.CSC6. (F) Percentage of single cell derived clones from
patient-derived primary ES cultures. Clones contained >5 cells and are
expressed as percentage of the total number of individual cells seeded;
results are presented as mean ± SD (n = 960 per ES culture). (G) Crystal
violet staining of primary ES colonies derived from ES culture 14 after
treatment with vehicle control, doxorubicin (200 nM) and vincristine
(200 nM) for 48 h. Cells were then washed and maintained in appropriate
media for an additional 7 days before fixing and staining with crystal
violet (0.25%, w/v methanol:ddH2O). Colony numbers were counted
using Quantity One Software. Results are shown as mean ± standard error
of the mean (SEM) of 3 independent experiments. (H) Surviving colonies
in paired patient-derived parent primary ES cells (n = 2) and ES-CSCs
(n = 6) following treatment with doxorubicin (200 nM). Results are
shown as mean ± SEM of 3 independent experiments. Black = parental
culture and matched ES-CSCs from sample 17, blue = parental culture
andmatched ES-CSCs from sample 23. (I) Surviving colonies inmatched
parent (n = 2) and paired ES-CSCs (n = 6) following treatment with
vincristine (200 nM) Results are shown as mean ± SEM of 3 independent
experiments. Black = parental culture and matched ES-CSCs from sam-
ple 17, blue = parental culture and matched ES-CSCs from sample 23. (J)
Light microscopy image of migrating ES cells (patient-derived primary
culture 15). (K) Migration index of patient-derived primary ES cultures
(n = 33). Results are shown as mean ± SEM of 3 independent experi-
ments. (L) Migration index of ES parent culture (n = 3) and paired ES-
CSCs (n = 11; mean ± SD). Red = parental cultures and matched ES-
CSCs from sample 11, black = parental cultures and matched ES-CSCs
from sample 17, blue = parental cultures and matched ES-CSCs from
sample 23
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2.7 Survival and statistical analyses
Results were linked to clinical outcome data in R (R version
3.4.0). The prognostic value of proteins was evaluated using
the Cox proportional hazards regression model, the optimal
cut-point in the data being determined using the Harrell’s C
index [39]. The Cox model was then performed using the
defined cut-point and Kaplan-Meier (KM) plots generated
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using the Survminer package and ggplot; Cox model confi-
dence intervals are included on each KM plot. The potential
association of targets with outcome was compared to each
other and with patient age and metastasis at diagnosis [40]
using a multivariable, univariate Cox model correcting for
multiple observations. Patients with missing clinical data were
excluded (n = 16). The number of patients included in each
KM analysis are given on each plot.
Statistically significant differences were determined using
a non-parametric Mann-Whitney two-tailed t-test or analysis
of variance (ANOVA) with a Tukey’s post-hoc test.
Correlations were determined using a Pearson’s correlation
coefficient (r). Non-linear regression analysis was used to
evaluate differences in viable cell number, proliferation and
response to chemotherapy. Statistical analyses were per-
formed using GraphPad PRISM 7.03 (GraphPad Software,
San Diego, USA).
3 Results
3.1 Patient-derived ES cell cultures express CD99 and
pathognomonic EWSR1-ETS gene fusions
Propagated patient-derived primary cells had a typical small
round cell morphology (69%; 22/32) with scant cytoplasm,
round nuclei, smooth distinct membranes and a single nucle-
olus [41]. Eighteen percent (6/32) were atypical (large irregu-
lar nuclei with vesicular chromatin) and 13 % (4/32) interme-
diate between typical and atypical. All cultures (32/32)
contained a translocation involving the EWSR1 gene from
chromosome 22q12 detected by FISH and/or RT-PCR
(Fig. 1 and Additional file 5, Table S2). Typical of ES, cells
were positive for membrane expression of CD99 (Fig. 1C),
which was confirmed byWestern blotting (Fig. 1D) and RNA
sequencing (Additional file 5, Table S2).
3.2 All patient-derived ES cell cultures contain a MDR
SR cell population
All patient-derived cultures contained cells that were capable
of SR from a single cell (Fig. 1E and F, mean progeny pro-
ducing cells per culture = 9 ± 8%, range 0.1–31%), consistent
with the premise that ES is a CSC driven cancer. Of these
single cell-derived cultures, 18 daughter progeny were ex-
panded and propagated for downstream analyses. In
Table 1 Highly expressed cell surface target genes in patient-derived primary ES cells and daughter ES-CSCs
Gene name and protein product Mean RNA read count in patient-derived
primary ES and ES-CSCs, determined by
total RNA sequencing.
Rank* STRING ICS with Fibrillin 1
FBN1 Fibrillin 1 313,166 11 –
COL6A3 Collagen type VI alpha 3 chain 296,145 13 0.615
COL12A1 Collagen type XII alpha 1 chain 295,027 14 0.567
ITGB1 Integrin subunit beta 1 160,061 27 0.930
COL6A2 Collagen type VI alpha 2 chain 138,252 30 0.595
LRP1 LDL receptor related protein 1 111,028 37 NI
CLIC4 Chloride intracellular channel 4 104,677 39 NI
COL6A1 Collagen type VI alpha 1 chain 99,781 45 0.634
LGALS1 Galectin 1 79,551 62 0.917
IGFBP4 Insulin like growth factor binding protein 4 74,656 67 0.911
Serpine2 Serpin family E member 2 73,506 70 NI
*Rank based onmean read count fromRNA sequencing. ICS = Interaction Confidence Score identified in STRING; 0 = least likely to be correct and 1 =
most likely to be correct. NI = no interaction reported in the STRING database
Fig. 2 Highly expressed cell surface proteins and validation of
differentially expressed mRNAs between ES and ES-CSCs. (A)
Interactions between proteins predicted to have high levels of cell
surface expression in patient-derived ES cells and ES-CSCs and low
expression in normal tissues (www.humanproteinatlas.org), generated
using the protein-protein interaction tool STRING database (http://
string-db.org) and visualised using Cytoscape v3.7.1 (www.cytoscape.
org). (B) Butterfly plot of mRNAs with signficant (adjusted p < 0.001)
differential expression in patient-derived parental ES and ES-CSCs.
Black circle = all differentially expressed genes with an adjusted p value
< 0.001. Dotted line = 2 fold increase (fold change of > 2) or 2 fold
decrease (fold change of < 2) in mRNA level in ES-CSCs compared to
ES cell cultures. Target mRNAs identified for validation by RT-qPCR are
labelled; blue and red circles. Grey circle = currently unannotated genes.
Quantification of target mRNAs using RT-qPCR in patient-derived pri-
mary ES and ES-CSCs; (C) neurexin-1 (NRXN1), (D) ELFN2, (E)
SLC38A11, (F) CCDC190, (G) TLR4 and (H) PIEZO2. Median gene
expression is reported as 2-ΔΔCt (results shown as median ± SD). RNA
expression was compared between populations using a non-parametric
Mann-Whitney two-tailed t-test
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agreement with the hypothesis that CSCs evade chemothera-
py, the SR ES cells were more resistant to both doxorubicin
(200 nM, mean colonies remaining = 44 ± 7% p = 0.03) and
vincristine (200 nM, mean colonies remaining = 41 ± 8%
p = 0.07) than the matched parental cells (mean colonies re-
maining = 20 ± 12% and 17 ± 10%, respectively; Fig. 1G, H, I
and Additional file 5, Table S2). Consistent with a MDR phe-
notype, there was a correlation between the effect of doxoru-
bicin and vincristine (R2 = 0.8478; Additional file 5,
Table S2). Hereafter these drug resistant daughter cells, with
single cell SR ability are referred to as ES-CSCs.
All primary patient-derived ES cell cultures contained mi-
gratory cells, with a mean MI of 34 ± 25, range 7.8–100 (Fig.
1J, K and Additional file 5, Table S2). However, there was no
statistically significant difference between the MI of patient-
derived primary ES cultures and daughter ES-CSCs
(12.7 ± 7.3, range 3.42–30.54, p = 0.09; Fig. 1L).
3.3 Parental ES and daughter ES-CSCs share
transcriptional profiles of mesenchymal stem cells
Parental ES cells and daughter ES-CSCs share a transcription-
al fingerprint of embryonic stem cells ([42, 43]; ESCs) and
mesenchymal stem cells ([13, 44]; MSCs), consistent with the
hypothesis that ES arise in cells of mesoderm origin. The
prognostic significance of MSC and ESC associated genes
shared by primary ES cells was examined in a publicly avail-
able RNA dataset of diagnosis ES tissues (GSE17618,
Additional file 6, Table S3). In these data c-KIT predicted
event free survival (EFS; Kaplan-Meier (KM) p = 0.012,
Hazard ratio (HR) = 2.37 and HR associated p value = 0.015)
and overall survival (OS; KM p = 0.039, HR = 2.21 Hazard
ratio p value (HRp) = 0.044), suggesting that genes of the
mesenchymal lineage may be candidate biomarkers of poor
outcome. However, in a phase II trial of imatinib mesylate,
which inhibits c-KIT, platelet derived growth factor receptors
and BCR-ABL, only 1/24 ES patients responded [45] and in a
second study of 13 ES patients no responses were observed
[43]. The hypothesis that genes of the mesenchymal lineage
expressed by ES cells may be candidate risk biomarkers and/
or therapeutic targets requires further investigation.
3.4 Identification of ES and ES-CSC specific cell surface
proteins as putative biomarkers and candidate
targets for therapy
Since cancer cell-surface proteins (the so called cancer cell
surfaceome) may represent attractive targets and biomarkers
for anti-cancer treatment [34, 46], we interrogated our RNA
sequencing data to identify genes predicted to be highly
expressed in all ES and ES-CSCs. Genes were ranked on
mean read count, localisation at the cell surface (with gold
status using the Surfaceome database; [34]) and reported to
have low or no expression in normal tissues (expression in < 5
normal tissues; Human Protein Atlas). Analysing our panel of
patient-derived primary ES cell cultures and ES-CSCs, we
identified 11 genes for further investigation (Table 1).
Although no specific gene ontology (GO) pathway terms were
represented in this list, 8/11 identified genes have been report-
ed to interact (STRING database, http://string-db.org [33],
ICS > 0.5; Fig. 2A), including the top hit FBN1 which is
associated with 7/8 partners in the list (Table 1, Fig. 2A),
Table 2 High differentially expressed RNAs between patient-derived primary ES cells and ES-CSCs
RNA expression determined by comparison
of total RNA sequencing of patient-derived primary
ES cells and ES-CSCs(1 = increased, 0 = decreased)




ES-CSCs and parental cells
Adjusted p value
1 ELFN2* 9.2 0.00016249
1 NRXN1* 3 4.07×10−10
1 SLC38A11* 3.4 1.40×10−12
1 PIEZO2 2.4 2.43×10−8
1 TLR4 2.4 1.06×10−13
1 CCDC190* 2.1 6.17×10−9
0 SLC1A3 0.39 7.95×10−10
0 LRRC32 0.4 2.15×10−9
0 PIK3IP1 0.45 6.59×10−10
Summary of RNA sequencing outputs identifying the greatest differentially expressed target genes using DeSeq2, ranked in the top 100 genes for fold
change and adjusted p value comparing ES and ES-CSC RNA profiles. Bold = targets with increased expression in ES-CSCs chosen for quantification
using RT-qPCR.* = targets confirmed as increased in ES-CSCs byRT-qPCR and further validated at the protein level by ICC and IHC using cell cultures
and ES taken at diagnosis, respectively
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suggesting that these genes are part of the same cellular path-
ways. Exploring the surfaceome of ES cell lines, 10 cell sur-
face genes with high expression in ES cells compared to
MSCs have previously been explored as candidate therapeutic
targets [34]. We confirmed expression of 9/10 of these genes
in patient-derived primary ES and ES-CSCs, 7 of which we
predict will be part of the ES surfaceome (Additional file 7,
Table S4).
3.5 Identification of candidate genes driving the ES-
CSC phenotype
Comparison of the total RNA profiles of ES and matched ES-
CSCs revealed 561 differentially expressed genes (adjusted p
value < 0.001), representing 1.5% (561/36575) of all genes
detected in ES and ES-CSCs. To prioritise genes that are dif-
ferentially expressed in ES compared to ES-CSCs for further
investigation, genes were ranked based on significance (ad-
justed p value) and fold change in expression at the RNA level
(from DESeq2 analysis; Burchill, Susan and Roundhill,
Elizabeth (2020): DeSeq2 output comparing the total RNA
sequencing gene expression data of paired patient-derived pri-
mary Ewing sarcoma cultures and Ewing sarcoma CSCs.
University of Leeds [Dataset]. https://doi.org/10.5518/886).
Of the 561 differentially expressed genes, 9 were identified
in the top 100 differentially expressed genes based on both
fold change in normalised read-count and adjusted p value
(Fig. 2B). Expression of 6 of these 9 genes was significantly
increased in ES-CSCs compared to parental cultures
(Table 2). Since we were seeking genes that are highly differ-
entially expressed and might be used to select patients for
targeted treatment, we went on to confirm the expression of
these 6 genes at the RNA and protein level and investigate
their potential association with clinical outcome.
RNA e x p r e s s i o n q u a n t i f i e d b y RT - q PCR
(Additional file 8, Table S5) and from total RNA sequencing
was found to be highly correlated; Neurexin-1 (NRXN1)
R2 = 0.92, Extracellular Leucine Rich Repeat and
Fibronectin Type III Domain Containing 2 (ELFN2)
R2 = 0.87, Coiled-coil Domain Containing 190 (CCDC190)
R2 = 0.78, Solute Carrier Family 38 Member 11 (SLC38A11)
R2 = 0.90, Toll Like Receptor 4 (TLR4) R2 = 0.74, Piezo Type
Mechanosensitive Ion Channel Component 2 (PIEZO2)
R2 = 0.93. Furthermore, the median expression of 5/6 of these
RNAs was increased in the ES-CSC populations compared to
the parental ES cell cultures, validating the approach we have
taken to identify genes increased in ES-CSCs. Expression of
neurexin-1 was elevated 13 fold (p < 0.001, Fig. 2C), ELFN2
34 fold (p < 0.001, Fig. 2D), SLC38A11 9 fold (p < 0.0001,
Fig. 2E), CCDC190 4 fold (p = 0.0002, Fig. 2F) and TLR4 1.9
fold (p = 0.0007, Fig. 2G) in the ES-CSCs compared to pa-
rental patient-derived primary ES cells. As the fold increase or
decrease in expression of PIEZO2 and TLR4 messenger
RNAs (mRNAs), respectively, was less than 2-fold, PIEZO2
and TLR4 were excluded from further downstream analyses.
Expression of the remaining four candidate genes was con-
firmed at the protein level by ICC in patient-derived paired
primary ES and ES-CSCs. Positive expression and subcellular
localisation of neurexin-1 (100%, cytoplasmic and nuclear
expression, H-score = 212 ± 39, range 80–300; Fig. 3A),
ELFN2 (97%, plasma membrane, cytoplasmic and nuclear
H-score = 219 ± 52, range 0–300), CCDC190 (85%, intracel-
lular, H-score = 39 ± 20, range 0–100) and SLC38A11 (85%,
plasma membrane and cytoplasmic, H-score = 87 ± 49, range
0–300) was confirmed in ES cultures (Table 3 and
Additional file 8, Table S5). At the protein level neurexin-1
was most significantly increased in ES-CSCs compared to
parental ES cells (p = 0.02; Fig. 3A, B).
Since neurexin-1α and neurexin-1β isoforms are tran-
scribed from the same gene (NRXN1) [47], we went on to
evaluate which isoforms were expressed in patient-derived
primary ES cells by RT-qPCR. The dominant isoform was
neurexin-1α (10/11 primary cel l cul tures; mean
2-ΔΔCt = 0.00731, range 0.00002–0.01219, p = 0.02).
However, since neurexin-1β was detected in 4/11 cultures
(mean 2-ΔΔCt = 0.06194, range 0.00224–0.72034) we decided
to use a pan-neurexin-1 antibody which detects both neurexin-
1α and neurexin-1β for Western blotting, IHC and ICC.
Despite some evidence of redundancy in the neurexin family
[48], neither neurexin-2 nor neurexin-3 were found to be dif-
ferentially expressed in the ES-CSCs (adjusted p value
> 0.001, results not shown).
Having confirmed increased expression of four candidate
driver genes at the protein level in ES-CSCs, we examined
their expression and potential association with outcome in a
panel of ES tissues taken at diagnosis. All proteins were de-
tected at the subcellular locations predicted from the
surfaceome analysis of RNA sequencing data [31], reported
in the literature and proteinatlas.org (Table 3). Most ES
expressed neurexin-1 (96%) and ELFN2 (96%), whereas
SLC38A11 and CCDC190 were detected in just 41% and
67% of the tumours examined, respectively (Table 3 and
Additional file 8, Table S5).
3.6 Association of candidate drivers of the ES-CSC
phenotype with clinical outcome
We found that the expression of neurexin-1 in tumours was
heterogeneous, localised to the plasma membrane, cytoplasm
and occasionally the nucleus. Increased levels of expression
were frequently observed in small groups of cells (Table 3,
Fig. 3B and Additional file 9, Table S6). High neurexin-1
expression, defined as samples with a H-score > 153 (Fig.
3C), was associated with a reduced time to first event,
predicting EFS (KM p = 0.027, HR = 3.86 HRp = 0.039)
and related to a worse OS (KM p = 0.056, HR = 3.731


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































HRp = 0.071; Fig. 3E). In this initial dataset this was indepen-
dent of patient age and presence of metastasis at diagnosis
(HR = 2.0 HRp = 0.05), although there was some association
with pelvic primary tumour site (HR = 0.9 HRp = 0.2), which
is a known predictor of poor outcome in ES [25].
Expression of ELFN2was also heterogeneous (Table 3 and
Additional file 9, Table S6). Low expression of ELFN2 was
significantly associated with a worse OS (KM p = 0.04,
HR = 0.3 HRp = 0.052), but not with time to a first event
(Table 3). CCDC190 and SLC38A11 (Table 3 and
Additional file 9, Table S6) were only detected in single or
small clusters of ES cells within the tumour, consistent with
the hypothesis that these proteins are expressed by ES-CSCs
and are, therefore, candidate therapeutic targets to eradicate
ES-CSCs. However, SLC38A11 did not predict EFS or OS
and, although low expression of CCDC190 was associated
with EFS (KM p = 0.034, HR = 0.26 HRp = 0.046), it was
not predictive of OS (Table 3). These observations require
further investigation in a larger cohort.
3.7 Validation of neurexin-1 as a prognostic factor
Neurexin-1 was the only prioritised target that, when
expressed at high levels in tumours at diagnosis, was associ-
ated with an adverse outcome (EFS and OS). We therefore
went on to evaluate the prognostic potential of neurexin-1 in a
second tumour cohort. In this cohort FFPE ESwere employed
to test the suitability of neurexin-1 IHC for analysis in FFPE
tumours. The pattern of neurexin-1 in FFPE tissues was sim-
ilar to that in frozen tumours. High expression of neurexin-1
(89% ES positive, mean H-score = 87.9 ± 45; Fig. 3D and
Additional file 9, Table S6) when dichotomising expression
using the previously defined H-score of 153 remained predic-
tive of EFS (KM p = 0.016, HR = 3.49 HRp = 0.02) and OS
(KM p = 0.022, HR = 3.22 HRp = 0.03; Fig. 3F). In the
publicly available RNA dataset of ES diagnosis tissues
(GSE17618), neurexin-1 mRNA was also predictive of both
EFS (KM p = 0.0093, HR = 2.71 HRp = 0.012) and OS (KM
p = 0.027, HR = 2.5 HRp = 0.033).
3.8 High neurexin-1 expression predicts relapse in
patients with localised disease
Combining patients diagnosed with localised disease from
tissue sample cohorts 1 and 2 revealed that neurexin-1 was
predictive of EFS (n = 41, 18/41 relapsed, KM p < 0.0001,
HR = 9.7 HRp < 0.0001) and OS (n = 42, KM p < 0.0001,
HR = 14 HRp < 0.0001, Fig. 3G). For those patients with
localised disease who have not had an event to date, 91%
(20/23) had low neurexin-1 expression and a mean EFS of
> 7 years. These observations suggest that neurexin-1 expres-
sion in tumours at diagnosis could be used for the early iden-
tification of patients with localised disease that relapse and
may benefit from more intensive treatment or rapid transfer
to early phase clinical trials of novel agents.
3.9 Functional evaluation of neurexin-1 using shRNA
and siRNA
To investigate the functional relevance of neurexin-1 we first
employed shRNA targeting of the NRXN1 gene to reduce the
expression of neurexin-1 in two patient-derived primary ES
cultures, parental.17 and parental.23. Cells were also infected
with a scramble shRNA, which was included in all experi-
ments as a control (shControl).
Decreased expression of neurexin-1 was confirmed by ICC
of cells (Fig. 4A) and Western blotting of proteins extracted
from shNRXN1 and shControl infected cells (Fig. 4B). The
partial shRNA knock-down of neurexin-1 was associated with
a decrease in shNRXN1.17 and shNRXN1.23 viable cell
numbers (fold change in shNRXN1 cell number over 72 h =
2.46 ± 0.2 and 1.42 ± 0.08, respectively) compared to control
infected cells (fold change in shControl cell number over
72 h = 3.21 ± 0.3 and 1.7 ± 0.08, respectively; p < 0.05, Fig.
4C). Cells with reduced levels of neurexin-1 protein
(shNRXN1 cells) compared to control cells (shControl) were
alsomore resistant to the cytotoxicity of doxorubicin (EC50 =
19 nM and 11 nM, respectively, 1.7 fold change in resistance,
p < 0.0001, Fig. 4D and F) and vincristine (EC50 = 8 nM and
0.3 nM, > 25 fold change in resistance, p = 0.001, Fig. 4E and
F). This increase in resistance may correlate with reduced cell
cycle progression and viable cell numbers in shNRXN1 cells
compared to shControl cells, although it did not correlate with
cell proliferation, which was not statistically different in
shNRXN1 (shNRXN1.17 20 ± 0.3%, shNRXN1.23 26
± 0.8%) and shControl (shControl.17 17 ± 1%, shControl.23
26 ± 0.2%) cells. Together these observations suggest that
neurexin-1 plays a role in ES cell survival and/or cell death
pathways, which may trigger responses to standard-of-care
chemotherapeutics independent of proliferation. This notion
requires further investigation.
To evaluate the potential role of neurexin-1 in single cell
self-renewal, we wanted to use long-term stable shNRXN1
knock-down of patient-derived primary ES cells. Infection
of cultures parental.17 and parental.23 with shNRXN1 or
shControl significantly reduced the self-renewing capacity of
both cultures compared to noninfected cells at 21 days (Fig.
4G; p < 0.0001), suggesting that off-target activities of
shRNA, viral infection and/or incubation with puromycin re-
duces the single cell self-renewing capacity of primary ES
cells. Single cell self-renewal of ES cells in this substrate-
adherent 21 day assay, after partial knock-down of neurexin-
1, was not significantly different to that in shControl infected
cells (Fig. 4G), likely reflecting decreased viability of patient-
derived primary ES cells after infection with shRNA.
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To investigate whether neurexin-1 has a functional role in
self-renewal, we used siRNA to decrease expression in SH-
SY-5Y cells, which expresses high levels of neurexin-1. The
viability of SH-SY-5Y cells was not affected by the optimised
electroporation conditions, and partial knock-down (1.6 to 1.4
fold; p < 0.0001) of neurexin-1 was confirmed by RT-qPCR
up to 72 h in siNRXN1 compared to siControl electroporated
cells. Consistent with the decreased viable cell number in
shNRXN1 patient-derived primary ES cells compared to
shControl, siRNA knockdown of neurexin-1 in SH-SY-5Y
cells significantly decreased the viable cell number (fold
change in siNRXN1 cell number over 72 h = 2.64 ± 0.05)
compared to siRNA control electroporated cells (fold change
in siControl cell number over 72 h = 3.99 ± 0.22; p < 0.02,
Fig. 4H). As SH-SY-5Y cells do not form colonies in our
adherent self-renewing assay, we investigated the potential
role of neurexin-1 in self-renewal using a 3D spheroid assay.
Importantly, we found that spheroids formed in 100% of wells
following seeding of 10, 100 or 1000 siControl or siNRXN1
SH-SY-5Y cells. siNRXN1 knockdown, however, decreased
the spheroid sizes compared to those of siControl cells
(p < 0.005, Fig. 4H), consistent with the hypothesis that
neurexin-1 plays a role in the self-renewal and growth of 3D
spheroids.
These studies show that neurexin-1 can affect drug resis-
tance and 3D spheroid formation, consistent with a putative
role in ES-CSCs and highlighting the importance of investi-
gating the potential biological relevance of the neurexin-1
pathway in ES.
3.10 Neurexin-1 binding partners predict ES patient
outcome
Since expression of neurexin-1 was found to be associated
with outcomes in ES, we went on to investigate the expression
of neurexin-1 binding partners that regulate its subcellular
localisation and synaptic activity in tumour cohort 1, i.e.,
Amyloid Beta Precursor Protein Binding Family A Member
1 (APBA1), Neuroligin 4 X-linked (NLGN4X) and
Neurexophilin 3 (NXPH3). All three proteins were differen-
tially expressed in the cell membrane and cytoplasm of diag-
nosis tumours (Table 3, Fig. 5A and Additional file 9,
Table S6). Low expression of APBA1 or NLGN4X was as-
sociated with poor EFS and OS rates, dichotomising the data
using the optimal cut-off points and H-scores of 6 (EFS, KM
p = 0.0048, HR = 0.22 HRp = 0.009 and OS, KM p = 0.0019,
HR = 0.2 HRp = 0.005) and 184 (EFS, KM p = 0.023,
HR = 0.31 HRp = 0.030 and OS, KM p = 0.04, HR = 0.31
HRp = 0.05), respectively (Table 3). NXPH3 protein was
detected in single or small groups of cells within ES tumours,
but was not associated with EFS or OS in this small cohort
(Table 3 and Additional file 9, Table S6).
High expression of neurexin-1 and low expression of
NLGN4X identified the same patients in 26/44 cases (59%),
although the prognostic significance of NLGN4X was inde-
pendent of neurexin-1 (EFS p = 0.02 and OS p = 0.05). This
likely reflects the multiple binding partners of neurexin-1
compared to the more limited interactions of NLGN4X [49].
Like neurexin-1, the prognostic significance of NLGN4X ap-
peared to be independent of patient age and metastasis (EFS,
HR = 2.4, HRp = 0.01 and OS, HR = 2.5 HRp = 0.01).
4 Discussion
Using transcriptomic approaches, we revealed the surfaceome
of patient-derived ES primary cell cultures and ES-CSCs and,
by doing so, identified candidate biomarkers of risk and ther-
apeutic targets. We found that the synaptic adhesion protein
neurexin-1, and regulators of this pathway, were associated
with ES outcome. Neurexin-1 was found to be involved in
self-renewal and drug resistance, characteristics of CSCs.
Consistent with our hypothesis that ES-CSCs drive disease
progression and relapse, high expression of neurexin-1 de-
fined a previously unidentified group of patients with local-
ised disease at diagnosis who develop metastasis and relapse.
Supporting a role of the neurexin-1 pathway in ES progression
and relapse, reducing the expression of neurexin-1 increased
drug resistance independent of cell proliferation and decreased
3D spheroid formation and growth. In addition, we found that
low expression of the neurexin-1 binding partners APBA1
and NLGN4X were also associated with poor clinical
Fig. 3 Expression and prognostic potential of neurexin-1. (A)
Expression of neurexin-1 protein detected by ICC in patient-derived ES
cultures and matched primary ES and ES-CSC. (B) IHC of neurexin-1
expression in ES taken at diagnosis (frozen tumour = cohort 1,
FFPE = cohort 2). Representative images demonstrating low/negative
tissues (tumour 37.diagnosis (Dx) and 114.Dx) and highly positive tis-
sues (tumour 28.Dx and 115Dx); neurexin-1 protein detected by IHC
using antibody ABN161-I (Millipore). Nuclei are labelled with
haema t oxy l i n . Red a r r ows = pos i t i v e s t a i n i ng , b l a ck
arrows = subcellular localisation of protein, C = cytoplasmic,
N = nuclear, PM = plasma membrane. (C) Summary of neurexin-1 ex-
pression in ES taken at diagnosis (cohort 1) reported using H-score.
Dashed line = H-score of 153, which is the cut-off point with highest
concordance index in the Cox model. (D) Expression of neurexin-1 in ES
tissue taken at diagnosis (cohort 1 and cohort 2). Dashed line = H-score of
153 which is the cut-off point established using cohort 1.
Triangle = patients with localised disease at diagnosis who subsequently
relapsed (n = 19), square = patients with localised disease at diagnosis
who did not relapse (n = 22), circle = patients with metastasis at diagnosis
(n = 27). Kaplan-Meier plots of the time to a first event and overall
survival in days and hazard ratio based on neurexin-1 protein expression
detected by IHC in (E) cohort 1, (F) cohort 2 and (G) patients with
localised disease at diagnosis. Hazard ratios based on neurexin-1 protein
expression dichotomising H-scores based on the cut-off point determined
in the initial cohort (H-score = 153). Red line = neurexin-1 H-score ≤ 153,
blue line = neurexin-1 H-score > 153
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outcomes, consistent with the reported roles of this pathway in
cell migration, cell-cell adhesion and cell survival [50].
Parental patient-derived primary ES cultures and daughter
ES-CSCs share the transcriptional fingerprint of ESCs [42,
43] and MSCs [13, 44], consistent with the mesenchymal
origin of ES [51]. Furthermore, these cells retain the
EWSR1-ETS fusion transcript and cell surface expression of
CD99 with the tumours from which they were derived [11,
52]. Of the most highly expressed RNAs in patient-derived
cells with a predicted cell surface localisation and low expres-
sion in normal tissues, FBN1 was the highest ranked one.
FBN1 is an EWSR1-friend leukaemia integration 1 transcrip-
tion factor (FLI1) target gene [53], encoding a large protein
called fibrillin-1. Fibrillin-1 is secreted by cells into the extra-
cellular matrix where it binds with other proteins to form mi-
crofibrils, which provide support to many structures including
bones and tissues in which ES can arise. High expression of
fibrillin-1 has previously been reported in ES cell lines [54]
and to promote tumorigenesis and metastasis in some cancers,
including ovarian [55] and colorectal cancer [56].
The most highly expressed RNAs in ES and ES-CSCs
identified in this study play putative roles in the regulation
of cell-extracellular matrix interactions, consistent with the
function of the bone microenvironment in tumour initiation
and progression [57]. Their low expression in normal tissues
and association with an adverse outcome or phenotype, vali-
dates the strategy we have taken to identify candidate thera-
peutic targets. Forty percent (4/10) of the highly expressed cell
surface proteins were members of the collagen gene family,
previously reported to be upregulated in ES [58]. Integrin
subunit beta 1 (ITGB1) and galectin 1 (LGALS1), which form
complexes with collagens and regulate the structure and inter-
actions of cells with the extracellular matrix [59], were also
highly expressed in patient-derived primary ES cells. Both
ITGB1 and LGALS1 mediate cell proliferation, migration
and tumour progression [60, 61]. High expression of ITBG1
protein has also been linked to a worse outcome in a range of
adult cancers [62]. Serpine2, which we found to be highly
expressed in ES and ES-CSCs, is also highly expressed in
colorectal and breast cancers, where it is reported to promote
lymph node metastasis [63]. Furthermore, the activity of
Insulin like Growth Factor Binding Protein 4 (IGFBP4),
which was also highly expressed in ES and ES-CSCs, is reg-
ulated by proteins of the tumour microenvironment which
may include fibrillin-1 [64]. In ES, EWSR1-FLI1 induces
pappalysin-1 expression cleaving IGFBP4, releasing insulin
growth factor (IGF) signalling from inhibition to increase
growth and tumorigenicity [65]. This is consistent with the
established role of insulin growth factor signalling in the path-
ogenesis and progression of ES [66, 67].
Although previous studies have identified candidate prog-
nostic or therapeutic targets using Next Generation
Sequencing (NGS) technologies, this is the first report de-
scribing RNA expression profiling of patient-derived paired
ES primary cell cultures and ES-CSCs. Consistent with our
observations, RNA sequencing of 13 ES has previously re-
sulted in the identification of extracellular matrix genes to
predict adverse outcomes [67], underscoring the importance
of extracellular matrix and tumour microenvironment interac-
tions in ES. Interrogation of our dataset confirmed the expres-
sion of genes including those encoding urotensin 2, insulin-
like growth factor 2 and periostin [67] in ES and ES-CSCs
(Additional file 7, Table S4), although these were expressed at
lower levels than the top cell surface genes fibrillin 1, collagen
type VI alpha 3 chain and collagen type XII alpha 1 chain
identified using our pipeline. Periostin was, however,
expressed at high levels in patient-derived primary ES and
ES-CSCs, where it may regulate matrix proteins and ES
cell-matrix interactions [68]. High expression of the fibroblast
growth factor receptor 1 (FGFR1) gene has also been associ-
ated with relapse in ES [68]. Although FGFR1 mRNA was
detected at reasonable levels in ES and ES-CSCs
(Additional file 7, Table S4), it is also expressed in a range
Fig. 4 Reduced neurexin-1 expression decreases cell viability, in-
duces resistance to doxorubicin and vincristine and decreases the
formation of 3D spheroids. (A) Expression of neurexin-1 detected by
ICC in shControl and shNRXN1 primary ES cells. Red arrows = plasma
membrane neurexin-1 expression. (B) Western blot showing high expres-
sion of neurexin-1 in SH-SY-5Y positive control cells and partial knock-
down of neurexin-1 protein in shNRXN1 treated cells compared to
shControl cells. Equal protein loading was confirmed by probing the
Western blot for expression of β-actin. (C) The number of viable cells
after shNRXN1 knock-down compared to shControl cells over 72 h was
significantly decreased. Viable cell numbers were quantified using a
trypan blue exclusion assay; viable cell numbers are presented as ratio
of the viable cell number at 0 h. Results are given as mean ± SEM, for 3
independent experiments. Knockdown of neurexin-1 by shNRXN1 de-
creased the sensitivity of ES clones to (D) doxorubicin (10–100 nM) or
(E) vincristine (10–100 nM). In (D) and (E) colonies were incubated with
cytotoxic chemotherapy (0–100 nM) for 72 h, washed and maintained in
appropriate media for another 7 days before fixing, staining with crystal
violet and counting. (F) Representative images of shControl and
shNRXN1 derived colonies after incubation with vehicle control, doxo-
rubicin (25 nM) or vincristine (25 nM). (G) Effect of shNRXN1 and
shControl on single cell self-renewal after 21 days. Clones contained
> 5 cells and are expressed as percentage of the total number of individual
cells seeded; results are shown as mean ± SEM. Infection with shNRXN1
or shControl significantly decreased the colony forming capacity of both
patient-derived cultures (patient.17 and patient.23). (H) Decreased num-
ber of viable SH-SY-5Y cells after infection with siNRXN1 compared to
control siRNA treated cells over 72 h. Viable cell numbers are presented
as ratio of the viable cell number at 0 h. Results are given as mean ± SEM.
SH-SY-5Y siControl and siNRXN1 cells grew as monolayers and did not
form colonies. Representative images showing decreases in siNRXN1
SH-SY-5Y cell numbers following culture in adherent conditions for
10 days compared to siControl cells (scale bar = 500 μm). (I) The sizes
of SH-SY-5Y spheroids formed from siNRXN1 cells were significantly
decreased compared to those from siControl cells under low adherence
conditions. Representative images of siNRXN1 and siControl derived
SH-SY-5Y spheroids are shown (scale bar = 100 μm)
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of normal tissues, which may limit its therapeutic potential.
Supporting the role of prominin-1 (CD133) as a marker of ES-
CSCs and prognostic indicator [11], RNA expression of
prominin-1 mRNA in the GSE 17613 dataset was found to
be associated with poor outcome. However, it was rarely de-
tected in our patient-derived ES cells. On the other hand, al-
though low levels of ALDH were detected by RNA sequenc-
ing in the patient-derived ES cells, its high expression did not
predict outcome in the GSE17618 dataset. In contrast, read
counts and prognostic significance of the ABC transporter
proteins P-glycoprotein (Pgp) and multi-drug resistance
protein-1 (MRP1) (Additional file 6; Table S3), were consis-
tent with previous observations reporting the prognostic sig-
nificance of high levels of MRP1 [37, 46], but not Pgp [46] in
ES. These observations emphasise the importance of compar-
ing the prognostic and functional significance of candidate
biomarkers of risk with established clinical risk factors at di-
agnosis, to develop a high performance prognostic model
combining biology and clinical risk factors to predict patient
outcomes to meet personalised medical needs.
Of the 4 candidates most significantly differentially
expressed and validated in the paired ES and ES-CSC sam-
ples, neurexin-1 was the target gene with highest cell surface
protein expression that was associated with survival.
Identification of this novel prognostic biomarker validates
the transcriptomics approach we have taken. However, a lim-
itation of this strategy is loss of genes that are differentially
expressed at low levels but have substantial biological activi-
ty. The prognostic potential of neurexin-1 expression in FFPE
and frozen tumours demonstrates its suitability for transfer to
the clinic, where it may be used at diagnosis to identify pa-
tients with localised disease that will develop metastasis and
relapse [6] for more intensive or novel treatment. The inde-
pendent prognostic value of neurexin-1 is currently being
compared to other adverse prognostic factors in an interna-
tional collaboration, including gain of chromosome 1q and
loss of 16q [69, 70], cell-cycle and proliferation regulation
[70–73], stromal antigen 2 (STAG2) and p53 [22–24] and
expression of insulin like growth factor binding protein 3
(IGF2BP3) [74].
High expression of neurexin-1 has been linked with carci-
nogenesis, invasion and proliferation in breast cancer [75],
drug response in gastric cancer [76] and to be predictive of a
worse outcome in oral squamous cell carcinoma [77].
Supporting these observations, we found that neurexin-1 ex-
pression predicts outcome in patients and affects 3D spheroid
formation and resistance to cytotoxic chemotherapeutics. We
are currently investigating the biological relevance of the
neurexin-1 pathway in ES-CSCs using single cell transcripto-
mics and high-content imaging, and multicellular preclinical
models to investigate its role in cell survival, cell death and the
development of bone metastasis [78]. Deletion of the
neurexin-1 gene alters synapse function and neuronal connec-
tivity in astrocytes, leading to inhibition of differentiation
[79], supporting the established role of neurexin-1 in
neurodevelopmental diseases such as schizophrenia,
Tourette syndrome, epilepsy and autistic spectrum disorder
[49]. In normal cells, neurexin-1 expression is restricted pri-
marily to the pre-synaptic nerve terminal of the brain where it
is an essential regulator of synapse properties [80]. A diverse
mix of downstream neurexin-1 proteins is translated as a result
of alternative splicing and transcription through isoform-
specific promoters. These alternative transcriptional start sites
produce neurexin-1α (1477 amino acids) and the shorter
neurexin-1β (472 amino acids) proteins which are reported
to have distinct functional activities and expression profiles
[48, 49]. Both proteins can be presented on the surface of
the pre-synaptic membrane following binding to APBA1
(Fig. 5B), although neurexin-1α preferentially binds
neurexophilins such as NXPH3 and neurexin-1β to
neuroligins such as NLGN4X in the post-synaptic membrane
[49]. Consistent with the role of the neurexin-1 pathway in ES,
we found that low expression of the neurexin-1 binding part-
ners APBA1 and NLGN4X was associated with a poor out-
come. Tripartite expression of neurexin-1, APBA1 and
NLGN4X may be required for cell-cell communication in
ES, neurexin-1 being presented as a hetero-tetramer on the
pre-synaptic membrane by APBA1 and binding with
NLGN4X on the post-synaptic membrane (Fig. 5B). Since
neurexin-1 dependent pathways regulate pre- and post-
synaptic organisation, cell migration, motility and cell-cell
adhesion [50, 80, 81], we are currently investigating their role
in multicellular models and tumours. We are also evaluating
the independent prognostic value of neurexin-1 protein and
regulators of its pathway. Whether neurexin-1 can be
exploited therapeutically, by targeting the neurexin-1 pathway
or by targeted delivery of small molecules to improve out-
comes for some patients remains to be seen.
Fig. 5 Expression of neurexin-1 binding partners and summary of
their putative roles in ES. (A) IHC of NLGN4X, APBA1 and NXPH3
in ES taken at diagnosis; representative images of low and high
expressing tumours are shown. Red arrows = positive expression. (B)
Summary of proteins that bind and transport neurexin-1 to the pre-
synaptic membrane (ABPA1) and bind the pre-synaptic complex to in-
duce post-synaptic membrane activity (NLGN4X). Bold = levels of
neurexin-1 and associated binding partners identified in patients with
poor outcome; high expression of neurexin-1 and low levels of APBA1
and NLGN4X result in reduced synaptic activity. NLGN4X = Neuroligin
4 X-linked. APBA1 = Ameloid Beta Precursor Protein Binding Family A
Member 1. Neurexin-1 orange = Neurexin-1 bound to APBA1.
Neurexin-1 pink = Unbound neurexin-1. NLGN4X green = NLGN4X
bound to neurexin-1-APBA1 complex. NLGN4X blue = Unbound
NLGN4X. C = C-terminal/cytoplasmic domain and N = N-terminal of
the neurexin-1 protein. Black bi-directional arrow = binding of APBA1-
Neurexin-1 complex and NLGN4X across synaptic cleft. Red dotted
line = formation of APBA1-Neurexin-1-NLGN4X hetero-tetramer
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